The Pharma Data

JANUARY 17, 2021

Previously Rexgenero Ltd, a UK-based company pioneering the development of cell therapies to treat serious diseases such as cancer and chronic limb-threatening ischaemia (CLTI), the launch of Ixaka follows integration of its nanoparticle gene therapy business in France and a shareholder restructuring. A total of $15.4 A total of $15.4

Gene Therapy 40

Gene Therapy Gene In-Vivo Genetics 40

Drug Discovery World

JULY 5, 2023

Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research. MG: I am responsible for Agilent’s cancer segment. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent?

Research 98

Research Protein Scientist Immune Response 98

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52

The Pharma Data

MARCH 25, 2022

2-4 Evusheld was generally well-tolerated in the trial.(2-4). 2-4 Evusheld was generally well-tolerated in the trial.(2-4). There is a growing body of evidence from multiple independent in vitro and in vivo (animal model) studies supporting the potential of Evusheld to protect against the BA.1,

Antibody 52

Antibody In-Vivo Medicine Vaccination 52

The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 1-3 Evusheld was generally well-tolerated in the trial. 1-3 Evusheld was generally well-tolerated in the trial.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52

Delveinsight

FEBRUARY 11, 2021

Verily collaborates with Janssen to launch COVID-19 immune response study. Verily is partnering with Johnson & Johnson’s Janssen division to witness the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes. .

Gene Therapy 52

Gene Therapy Gene Immune Response In-Vivo 52

The Pharma Data

JUNE 17, 2022

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). However, immunocompromised individuals still lack effective immunity against SARS-CoV-2 infection.

Antibody 52

Antibody In-Vivo In-Vitro Immune Response 52

XTalks

FEBRUARY 27, 2024

TILs are immune cells that attack and penetrate tumors. The immune cells in both cases are then infused back into the patient. Amtagvi is approved for the treatment of unresectable or metastatic melanoma following prior treatment with a PD-1 inhibitor and a BRAF inhibitor if the tumor harbors a BRAF V600 mutation.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

The Pharma Data

DECEMBER 10, 2020

In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. Treatment vaccines : these boost the immune system responses to target cells. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Drug Discovery World

JULY 22, 2022

Immunotherapies have become more popular due to their ability to trigger and train the patient’s immune system to recognise and attack tumour cells, provide strong immune responses, and reduce the severity of adverse side effects generally associated with chemotherapies. Jespersen et al.

In-Vivo 52

In-Vivo Engineer In-Vitro Medicine 52

Pharma Marketing Network

DECEMBER 21, 2020

those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies. Here are 5 considerations when developing a communications strategy for a novel genetic medicine. #1.

Genetics 52

Genetics Medicine Gene Therapy Marketing 52

The Pharma Data

NOVEMBER 29, 2020

. Observed CMV-neutralizing antibody responses and tolerability profile are consistent with previous interim results. CMV can cause severe complications in kidney transplant recipients including organ rejection and death. NEW YORK and VIENNA, Austria, Nov. 30, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . And whilst clinical trials activity decreased by around 15% compared to 2020, last year still saw a number of regenerative medicines reach the bedside.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Discovery World

DECEMBER 15, 2022

Now, after nearly 35 years of research and more than a decade of preclinical progress, several different gene editing modalities are being tested in early phase clinical trials. Early phase clinical trials for gene editing therapies. Gene editing challenges and potential solutions. In one example, Choi et al.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

Drug Discovery World

FEBRUARY 15, 2023

Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. A healthy immune system is naturally primed to eliminate malignant and abnormal cells through a synchronised and dynamic interplay between adaptive and innate immunity.

Research 52

Research In-Vitro In-Vivo Development 52

The Pharma Data

JULY 8, 2021

Tezepelumab is being developed by Amgen in collaboration with AstraZeneca. executive vice president of Research and Development at Amgen. 8) There were no clinically meaningful differences in safety results between the tezepelumab and placebo groups in the NAVIGATOR trial.(8) Amgen (NASDAQ:AMGN) announced that the U.S.

Allergies 52

Allergies Trials In-Vivo Medicine 52

Drug Discovery World

FEBRUARY 2, 2023

Bryan Oronsky , Chief Development Officer at EpicentRx, discucsses how one drug sourced from the defense and aerospace industry, could have many potential disese targets. A late-stage clinical trial in head and neck cancer for the treatment of severe oral blistering or oral mucositis caused by radiation therapy is planned.

Manufacturing 52

Manufacturing Clinical Trials Clinical Trials Drugs 52

Pharma Marketing Network

JANUARY 20, 2021

In other areas of the industry (such as cell and genetic medicine development) progress continued at an impressively brisk pace despite the pandemic. Regarding OWS’s support for vaccine development, Dr Slaoui noted that 5 of the 6 vaccines selected (from a total of 94 programs) are currently in phase 3 development or approved.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52

The Pharma Data

OCTOBER 26, 2020

The purpose of this exploratory Phase 1b/2 trial was to evaluate the safety and efficacy of the combination of TG4001 and an immune checkpoint inhibitor in a heterogeneous group of patients with aggressive, recurrent and/or metastatic HPV16-positive cancers. Key findings of the trial: .

Vaccination 52

Vaccination Vaccine Trials Containment 52

The Pharma Data

APRIL 27, 2021

Progress on implementation of the Corporate Social Responsibility strategy. Strong increase in Q1 2021 business EPS ( 1) at CER. Q1 2021 sales increase of 2.4% at CER driven by growth drivers Dupixent ® and Vaccines. Specialty Care sales grew 15.3%, due to strong Dupixent ® performance (+45.6% to €1,047 million) and oncology launches.

Sales 52

Sales Vaccination Vaccine Medicine 52